Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy pipeline. Ulixacaltamide’s Essential3 data appear statistically robust, but a ...

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis specializes in using genetic insights to discover new therapies for neurological disorders. The biotech's efforts received a boost today when the U.S. Food and Drug Administration (FDA) granted ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the 14 best booming stocks to buy right now, with staggering three-month returns of over 420%. On January 12, Wedbush analyst Laura Chico lifted ...

Shares of Praxis Precision Medicines rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor. Praxis on ...

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal ...

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders ...

The investment seeks capital appreciation. The fund invests primarily in U.S. equity securities and seeks to reflect the performance of the U.S. large capitalization growth equities market, as ...

Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty ...

26 Oct 2021 12 Nov 2021 26 Nov 2021 Second interim dividend of 2.0 Sen per share tax-exempt for the financial year ended 31 December 2021 11 Nov 2021 25 Feb 2022 25 Mar 2022 08 Apr 2022 Third interim ...